What is Claimed is:

1. A pharmaceutical composition comprising an epothilone together with a pharmaceutically acceptable carrier, wherein the epothilone is provided in a therapeutically acceptable concentration upon administration to a patient.

2. The pharmaceutical composition of Claim 1 wherein the composition is administered orally.

3. The pharmaceutical composition of Claim 1, wherein the composition comprises at least one cyclodextrin.

4. The pharmaceutical composition of Claim 3, wherein the cyclodextrin is selected from the group consisting of β-cyclodextrin, hydroxypropyl–β-cyclodextrin, and sulfopropyl-β-cyclodextrin.

5. The pharmaceutical composition of Claim 4, wherein the epothilone is selected from the group consisting of epothilone D, epothilone B, 9,10-dehydro-epothilone D, and 9,10-dehydro-epothilone B.

6. The pharmaceutical composition of Claim 5, wherein the epothilone is epothilone D.

7. The pharmaceutical composition of Claim 6, wherein the cyclodextrin is hydroxypropyl–β-cyclodextrin.

8. The pharmaceutical composition of Claim 6, wherein the cyclodextrin is sulfopropyl–β-cyclodextrin.

9. A lyophilized mixture comprising an epothilone and a cyclodextrin.

10. The lyophilized mixture of Claim 9, wherein the cyclodextrin is selected from the group consisting of β-cyclodextrin, hydroxypropyl–β-cyclodextrin, and sulfopropyl-β-cyclodextrin.

11. The lyophilized mixture of Claim 10, wherein the epothilone is selected from the group consisting of epothilone D, epothilone B, 9,10-dehydro-epothilone D, and 9,10-dehydro-epothilone B.

12. The lyophilized mixture of Claim 11, wherein the epothilone is epothilone D.

13. The lyophilized mixture of Claim 12 , wherein the cyclodextrin is hydroxypropyl–β-cyclodextrin.

14. The lyophilized mixture of Claim 12 , wherein the cyclodextrin is sulfopropyl–β-cyclodextrin.

15. A method of preparing a pharmaceutical composition of Claim 1, said method comprising the steps of

obtaining a lyophilate of Claim 9; and

dissolving said lyophilate in a suitable reconstitution solvent.

16. The method of Claim 15, wherein the reconstitution solvent comprises one or more of an alcohol and a glycol.

17. The method of Claim 16, wherein the alcohol is ethanol and the polyene glycol is selected from the group consisting of propylene glycol, polyethylene glycol 400, and polyethoxyethylene sorbitan monooleate.

18. The method of Claim 17, wherein the glycol is polyethoxyethylene sorbitan monooleate.

19. The method of Claim 18, wherein the reconstitution solvent comprises water at between about 10% (v/v) and about 70% (v/v), and polyethoxyethylene sorbitan monooleate at between about 25% (v/v) and about 10% (v/v).

20. The method of Claim 19, wherein the reconstitution solvent comprises water, ethanol, and polyethoxyethylene sorbitan monooleate in a volume/volume/volume ratio selected from the group consisting of about 10/65/25, about 20/55/25, about 40/35/25, about 62.5/12.5/25, about 60/20/20, and about 60/25/15.

21. The method of Claim 20, wherein the reconstitution solvent comprises water, ethanol, and polyethoxyethylene sorbitan monooleate in a volume/volume/volume ratio of about 60/25/15.

22. A soft gel cap comprising a pharmaceutical composition of Claim 1.